Ifosfamide (ifosfamide)

Dosage of ifosfamide must be based on the clinical and hematologic response and tolerance of the patient in order to obtain optimum therapeutic response with minimal adverse effects. Although higher total doses of ifosfamide can be given by continuous infusion compared with short IV infusion with similar toxicity, the most effective dosage schedule has not been established. In patients who experience myelosuppression following a dose of ifosfamide, a subsequent course of the drug should not be administered until the patient's hematologic functions are within acceptable limits. (See Cautions: Precautions and Contraindications)

To minimize the risk of urotoxic effects, each dose of isosfamide must be accompanied by a mesna regimen. (See Dosage and Administration: Dosage, in Mesna 92:56)

Although ifosfamide has been used in a limited number of patients with renal and/or hepatic impairment, the manufacturer states that studies to determine the optimum dosage in such patients have not been conducted.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

Although ifosfamide has been used concurrently with other drugs, including other cytotoxic agents, without unusual adverse effects, the possibility of adverse drug interactions cannot be excluded.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Ifosfamide can cause fetal harm when administered to a pregnant woman, but potential benefits from use of the drug may be acceptable in certain conditions despite possible risk to the fetus. Ifosfamide has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits in doses 0.05-0.075 times the human dose. There are no adequate or controlled studies to date using ifosfamide in pregnant women. Ifosfamide should be used during pregnancy only in life-threatening situations or for disease for which safer drugs cannot be used or are ineffective. If the drug is administered during pregnancy or if the patient becomes pregnant while receiving ifosfamide, the patient should be informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during ifosfamide therapy.

Ifosfamide is distributed into milk. Because of the potential for serious adverse reactions to ifosfamide in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.